IgA nephropathy (IgAN) is an immune complex glomerulonephritis that is characterized by recurrent hematuria as the main clinical manifestation. In this study, we used the IgAN mouse model which was previously established to investigate the possible mechanism by which IgAN fibrosis correlates with decreased plasma gelsolin (pGSN) levels. We investigated the levels of pGSN, transforming growth factor β1 (TGFβ1), and oxidative stress markers including superoxide dismutase (SOD), catalase (CAT), glutathione (GSH), and malondialdehyde (MDA) in the serum and renal tissues of different groups. The between-group differences and correlations in the results for the IgAN group were analyzed with statistical methods. The pathological and urinalysis results obtained from the IgAN mouse model showed that this model conforms to the basic lesion characteristics observed in human IgAN. The serum pGSN levels and SOD, CAT, GSH levels in renal tissues were decreased in the IgAN group (P < 0.01), and pGSN, TGFβ1, MDA levels in renal tissues of the IgAN group were increased which compared with those in the other groups (P < 0.01). The correlation analysis for serum pGSN levels in the IgAN group showed a significant correlation with different test results (P < 0.01). The possible mechanism by which IgAN fibrosis correlates with decreased pGSN levels involves the regulation of TGFβ1 and oxidative stress.
D’AmicoG. Natural history of idiopathic IgAN: Role of clinical and histological prognostic factors. Am J Kidney Dis2000; 36: 227–37.
2.
YinHLStosselTP. Control of cytoplasmic actin gel-sol transformation by gelsolin, a calcium dependent regulatory protein. Nature1979; 281: 583–86.
3.
SnabesMCBoydAE3rdBryanJ. Detection of actin-binding proteins in human platelets by 125I-actin overlay of polyacrylamide gels. J Cell Biol1981; 90(3): 809–12.
McGoughAMStaigerCJMinJKSimonettiKD. The gelsolin family of actin regulatory proteins: Modular structures, versatile functions. FEBS Lett2003; 552(2–3): 75–81.
6.
OsbornTMVerdrenghMStosselTPTarkowskiABokarewaM. Decreased levels of the gelsolin plasma isoform in patients with rheumatoid arthritis. Arthritis Res Ther2008; 10(5): 1–9.
7.
BuckiRLeventalIKulakowskaAJanmeyPA. Plasma gelsolin: Function, prognostic value, and potential therapeutic use. Curr Protein Pept Sci2008; 9: 541–51.
8.
SuhlerELinWYinHLLeeWM. Decreased plasma gelsolin concentrations in acute liver failure, myocardial infarction, septic shock, and myonecrosis. Crit Care Med1997; 25: 594–98.
9.
MounzerKCMoncureMSmithYRDinubileMJ. Relationship of admission plasma gelsolin levels to clinical outcomes in patients after major trauma. Am J Respir Crit Care Med1999; 160: 1673–81.
10.
DiNubileMJStosselTPLjunghusenOCFerraraJLAntinJH. Prognostic implications of declining plasma gelsolin levels after allogeneic stem cell transplantation. Blood2002; 100: 4367–71.
11.
Christofidou-SolomidouMScherpereelASolomidesCCMuzykantovVRMachtayMAlbeldaSMDiNubileMJ. Changes in plasma gelsolin concentration during acute oxidant lung injury in mice. Lung2002; 180: 91–104.
LeePSWaxmanABCotichKLChungSWPerrellaMAStosselTP. Plasma gelsolin is a marker and therapeutic agent in animal sepsis. Crit Care Med2007; 35: 849–55.
14.
BöttingerEPBitzerM. TGF-ß signaling in renal disease. J Am Soc Nephrol2002; 13: 2600–10.
15.
SharmaRKhannaASharmaMSavinVJ. Transforming growth factor-beta1 increases albumin permeability of isolated rat glomeruli via hydroxyl radicals. Kidney Int2000; 58(1): 131–36.
16.
OikonomouNThanasopoulouATzouvelekisAHarokoposVPaparountasTNikitopoulouIWitkeWKaramerisAKotanidouABourosDAidinisV. Gelsolin expression is necessary for the development of modelled pulmonary inflammation and fibrosis. Thorax2009; 64: 467–75.
17.
ChauhanVJiLChauhanA. Anti-amyloidogenic, anti-oxidant and anti-apoptotic role of gelsolin in Alzheimer’s disease. Biogerontology2008; 9(6): 381–89.
18.
ZhangLYeFHeYKongDHanCZhaoZZhuJLiuXJinX. Establishment of a mouse IgA nephropathy model with MBP-20-peptide fusion protein. Anat Rec2010; 293: 1729–37.
19.
KoyamaASharminSSakuraiHShimizuYHirayamaKUsuiJNagataMYohKYamagataKMuroKKobayashiMOhtaniKShimizuTShimizuT. Staphylococcus aureus cell envelope antigen is a new candidate for the induction of IgA nephropathy. Kidney Int2004; 66: 121–32.
20.
LivakKJSchmittgenTD. Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C(t)) method. Methods2001; 25: 402–8.
21.
JennetteJC. The immunohistology of IgAN. Am J Kidney Dis1988; 12: 348–52.
22.
MiyawakiSMusoETakeuchiEMatsushimaHShibataYSasayamaSYoshidaH. Selective breeding for high serum IgA levels from noninbred ddY mice: Isolation of a strain with an early onset of glomerular IgA deposition. Nephron1997; 76(2): 201–7.
23.
LeePFDragerLRStosselTPMooreFDRogersSO. Relationship of plasma gelsolin levels in outcomes of critically ill surgical patients. Ann Surg2006; 243: 399–403.
24.
WynnTARamalingamTR. Mechanisms of fibrosis disease: Therapeutic translation for fibrotic. Nat Med2013; 18(7): 1028–40.
25.
WynnTA. Cellular and molecular mechanisms of fibrosis. J Pathol2008; 214: 199–210.
26.
WangWKokaVLanHY. Transforming growth factor-beta and Smad signalling in kidney diseases. Nephrology2005; 10(1): 48–56.
27.
RobertsAB. The ever-increasing complexity of TGF-beta signaling. Cytokine Growth Factor Rev2002; 13: 3–5.
28.
FukasawaHYamamotoTSuzukiHTogawaAOhashiNFujigakiYUchidaCAokiMHosonoMKitagawaMHishidaA. Treatment with anti-TGF-beta antibody ameliorates chronic progressive nephritis by inhibiting Smad/TGF-beta signaling. Kidney Int2004; 65: 63–74.
29.
ZhouAUenoHShimomuraMTanakaRShirakawaTNakamuraHMatsuoMIijimaK. Blockade of TGF-beta action ameliorates renal dysfunction and histologic progression in anti-GBM nephritis. Kidney Int2003; 64: 92–101.
30.
GrygielkoETMartinWMTweedCThorntonPHarlingJBrooksDPLapingNJ. Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis. J Pharmacol Exp Ther2005; 313: 943–51.
31.
LiJCampanaleNVLiangRJDeaneJABertramJFRicardoSD. Inhibition of p38 mitogen-activated protein kinase and transforming growth factor-β1/Smad signaling pathways modulates the development of fibrosis in adriamycin-induced nephropathy. Am J Pathol2006; 169: 1527–40.
32.
DrydenGWJrDeaciucIArteelGMcClainCJ. Clinical implications of oxidative stress and antioxidant therapy. Curr Gastroenterol Rep2005; 7: 308–16.
33.
ForsbergLdeFaireUMorgensternR. Oxidative stress, human genetic variation, and disease. Arch Biochem Biophys2001; 389: 84–93.
34.
ChenJXZhouJFShenHC. Oxidative stress and damage induced by abnormal free radical reactions and IgA nephropathy. J Zhejiang Univ Sci B2005; 6: 61–68.
35.
VasTWagnerZJeneiVVargaZKovácsTWittmannISchinzelRBallaGBallaJHeidlandANagyJ. Oxidative stress and non-enzymatic glycation in IgA nephropathy. Clin Nephrol2005; 64: 343–51.
